Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.

Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, Chen D, Weinstein J, Shore J, da Silva B, Belsey E, McComsey GA, Murphy RL.

J Antimicrob Chemother. 2009 Jun;63(6):1244-50. doi: 10.1093/jac/dkp100. Epub 2009 Mar 25.

PMID:
19321503
2.

[Tenofovir as a strategy to avoid or limit adverse effects].

Portilla J.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:19-24. Review. Spanish.

PMID:
19195434
3.

Tenofovir: what have over 1 million years of patient experience taught us?

Pozniak A.

Int J Clin Pract. 2008 Aug;62(8):1285-93. doi: 10.1111/j.1742-1241.2008.01817.x. Review.

PMID:
18705824
4.

The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.

Chetchotisakd P.

Expert Rev Anti Infect Ther. 2009 Sep;7(7):801-5. doi: 10.1586/eri.09.66. Review.

PMID:
19735222
5.

[Are all analogue combinations equal?].

Miralles Alvarez C.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:38-44. Review. Spanish.

PMID:
19195437
6.

Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

Sattler FR.

Top HIV Med. 2008 Oct-Nov;16(4):127-33. Review.

7.

Switching strategies to improve lipid profile and morphologic changes.

Barragan P, Fisac C, Podzamczer D.

AIDS Rev. 2006 Oct-Dec;8(4):191-203. Review.

PMID:
17219734
8.

[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].

Pulido F, Fiorante S.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:13-8. Review. Spanish.

PMID:
19195433
9.

Antiretroviral-therapy-associated lipoatrophy: current status and future directions.

Nolan D, Mallal S.

Sex Health. 2005;2(3):153-63. Review.

PMID:
16335543
10.

The reassurance of experience.

Martínez E.

Int J STD AIDS. 2003 Oct;14 Suppl 1:20-8. Review.

PMID:
14617400
11.

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G.

Clin Infect Dis. 2006 Jan 15;42(2):283-90. Epub 2005 Dec 8. Review.

PMID:
16355343
12.

[Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].

Bernardino de la Serna JI, Mora Rillo M, Arribas López JR.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:7-12. Review. Spanish.

PMID:
19195432
13.

Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations.

Caron-Debarle M, Boccara F, Lagathu C, Antoine B, Cervera P, Bastard JP, Vigouroux C, Capeau J.

Curr Pharm Des. 2010 Oct;16(30):3352-60. Review.

PMID:
20687886
14.

[Renal toxicity in HIV-infected patients receiving HAART including tenofovir].

Madeddu G, Quirino T, Carradori S, Ricci E, Grosso C, Penco G, De Socio G, Rossella E, Palvarini L, Marconi P, Melzi S, Mura MS, Bonfanti P; Gruppo CISAI.

Infez Med. 2006 Sep;14(3):125-34. Review. Italian.

15.

Renal toxicity associated with tenofovir use.

Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V.

Expert Opin Drug Saf. 2010 Jul;9(4):545-59. doi: 10.1517/14740331003627458. Review.

PMID:
20384533
16.

Tenofovir-related nephrotoxicity: case report and review of the literature.

James CW, Steinhaus MC, Szabo S, Dressier RM.

Pharmacotherapy. 2004 Mar;24(3):415-8. Review.

PMID:
15040657
17.

Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy.

McComsey G.

AIDS Rev. 2002 Jul-Sep;4(3):140-7. Review.

PMID:
12416448
18.

[Tenofovir: pharmacology and interactions].

Azanza JR, García Quetglas E, Sádaba B, Gómez-Giu A.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:2-6. Review. Spanish.

PMID:
19195431
19.

Interventions for managing antiretroviral therapy-associated lipoatrophy.

Sutinen J.

Curr Opin Infect Dis. 2005 Feb;18(1):25-33. Review.

PMID:
15647696
20.

Mitochondria and HIV infection: the first decade.

Cossarizza A, Troiano L, Mussini C.

J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):18-24. Review.

PMID:
12003168

Supplemental Content

Support Center